Prognostic performance of <scp>FIGO</scp> 2023 endometrial carcinoma staging: a comparison to <scp>FIGO</scp> 2009 staging in the setting of known and unknown molecular classification
Downstaging based on POLE mutation more accurately represents patient outcomes. However, in the absence of known POLE status, applying molecular-agnostic FIGO 2023 criteria for stage I/II disease should be conducted with caution. For aggressive histotypes, additionally reporting FIGO 2009 stage should be considered. Upstaging based on substantial lymphovascular space invasion, aggressive histotype with any myometrial invasion and abnormal p53 improves prognostic discernment. Further subdivisions within stage I/II provide minimal additional prognostic information.
Authors
- Caressa Hui (ORCID: https://orcid.org/0000-0002-3864-4720)
- Elizabeth Kidd (ORCID: https://orcid.org/0000-0003-4749-4098)
- Diane Libert (ORCID: https://orcid.org/0000-0002-1554-2502)
- Vivek Charu (ORCID: https://orcid.org/0000-0002-7147-9026)
- Brooke E. Howitt (ORCID: https://orcid.org/0000-0002-0309-6680)
- Ann K. Folkins (ORCID: https://orcid.org/0000-0003-3537-8778)
- Teri A. Longacre (ORCID: https://orcid.org/0000-0002-0935-7300)
- Phoebe M. Hammer (ORCID: https://orcid.org/0000-0002-4206-2002)
- Eric Yang (ORCID: https://orcid.org/0000-0001-9896-0365)
Institutions
- Stanford University (US)
Publication Details
- Journal
- Histopathology
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1111/his.15302
- Citations
- 9
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.24